Volume 1 | Issue 3 | DOI: https://doi.org/10.33696/Neurol.1.014
Microptofluidic Technology for Biodiagnostics of Traumatic Brain Injury: A Commentary
- 1School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
P. Goldberg Oppenheimer, GoldberP@bham.ac.uk
Received Date: May 15, 2020
Accepted Date: July 02, 2020
Oppenheimer PG. Microptofluidic Technology for Biodiagnostics of Traumatic Brain Injury: A Commentary. J Exp Neurol. 2020;1(3): 80-88.
Copyright: © Oppenheimer PG. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cancer is a worldwide public health issue that affects millions of people every year. In 2018 there were 17 million newly documented cases of cancer globally (8.8 million in men and 8.2 million in women), leading to 9.6 million deaths. Cancer is a vastly heterogeneous disease, with over 100 different types of cancer currently identified in humans; the most common types of cancer are lung, female breast, bowel and prostate, these four types account for more than 40% of all new cancer case
By deduction from complexity of (behavioral) models, we develop an entropic computational tool to distinguish erroneous/redundant eye movements from task relevant eye movements.
Breast Cancer is the most regularly diagnosed type of cancer in women in the world, making up on its own 25% of all cases, or nearly 2 million new cases in 2018, and 15% of all cancer related deaths, or around 626,700 deaths for that same year.
No Studies in Stroke Regarding Brain fMRI Activity and Pelvic Floor Muscle Training/Activation - Only Studies in Non-stroke Population: A Review of Neuroimaging Studies
Neurogenic lower urinary tract dysfunction (NLUTD) is highly prevalent in poststroke patients, leading to major impact on the quality of life (QoL) and healthcare resources. Pelvic floor muscle training (PFMT) has, over the past two decades, been recommended as first-line treatment for neurologically healthy patients with lower urinary tract symptoms (LUTS).
How medications whose major biologic effect is to reduce bile acid synthesis favorably affect the course of a variety of cholestatic and metabolic liver diseases is not immediately apparent. Also, the most frequently used plasma biomarkers for evaluating benefit, alkaline phosphatase and conjugated bilirubin , provide different information. The former may be misleading with respect to the course of the disease and therefore it is important to focus on the pathophysiologic basis for its use.